Home›Companies›Biotech & Pharma›Amlogenyx

Amlogenyx Inc.

Develops an investigational gene therapy for people with Alzheimer's disease.

Updated Nov 10, 2026·Latest SEC filing Jul 9, 2026·Suggest an edit

About Amlogenyx

Amlogenyx is a private company based in Novato, California, incorporated in 2023 in Delaware. It has reported $23,999,989 raised in two offerings on Form D since August 2024.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jul 1, 2026Jul 9, 2026$10,000,000of $20.0M target2$5.0MConvertible Promissory Notes and equity securities issuable upon conversion thereofRule 506(b)Form D ↗
Jul 26, 2024Aug 2, 2024$13,999,989fully sold4$3.4MEquityRule 506(b)Form D ↗
Total, two offerings$23,999,989

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Amlogenyx's Form D filed Jul 9, 2026.

John Pinion
John Pinion
Chief Operations Officer
Craig Gordon
Craig Gordon
Director
Also a board member at Rapalogix Health.
Emil Kakkis
Emil Kakkis
Founder and Chairman
TH
Ted Huizenga
Executive officer
KP
Karah Parschauer
Executive officer

Earlier filings also listed Tom Kassberg (president, last listed Aug 2024).

Sources

  1. SECAmlogenyx Inc. filing history
  2. CompanyAmlogenyx about
  3. CompanyAmlogenyx privacy policy